<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277637</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-11417-101</org_study_id>
    <nct_id>NCT04277637</nct_id>
  </id_info>
  <brief_title>Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies</brief_title>
  <official_title>A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability; Recommended Phase 2 Dose
      (RP2D), optimal ramp-up dosing schedule; and to evaluate preliminary activity of BGB-11417
      monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">June 26, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1a: Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1a: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1a: Number of participants experiencing AEs leading to discontinuation of BGB-11417</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>7. Phase 1a: Maximum Tolerated Dose (MTD) as Assessed by the Safety Monitoring Committee (SMC)</measure>
    <time_frame>Day 1 to 21 days target dose of the study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1a: Maximum RP2D of BGB-11417</measure>
    <time_frame>Day 1 to last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Optimal ramp-up schedule of BGB-11417</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
    <description>A ramp-up schedule is defined as the BGB-11417 dosing schedule a participant utilizes to gradually reach or &quot;ramp-up&quot; to the intended target dose and schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants Experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of participants experiencing AEs leading to discontinuation of BGB-11417</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Overall Response Rate (ORR) as Assessed by the Investigator</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
    <description>ORR is defined as the proportion of participants who had confirmed complete response Complete Response (CR) or Partial Response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Maximum Observed Plasma Concentration (Cmax) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Area Under the Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>: Phase 1a: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Time Taken for Half the Initial Dose Administered to Be Eliminated from The Body (T1/2) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Time to Maximum Plasma Concentration (Tmax) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Apparent Clearance (CL/F) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Apparent volume of distribution (Vz/F) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Steady State Area Under the Concentration-Time Curve of 0- Last Day (AUCLast, ss) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Steady State Maximum Observed Plasma Concentration (Cmax, ss) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Steady State Trough Observed Plasma Concentration (Ctrough, SS) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a; Steady State Time to Maximum Plasma Concentration (Tmax, ss) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Observed accumulation ratio based on Area under the curve (AUCRo) Cmax of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose following repeated dosing at each targeted dose levels</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1a: Observed accumulation ratio based on Cmax (RCmax) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose following repeated dosing at each targeted dose levels</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Overall Response Rate (ORR) as Assessed by the Investigator</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
    <description>ORR is defined as the proportion of participants who had confirmed complete response Complete Response (CR) or Partial Response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Progression-Free Survival (PFS)</measure>
    <time_frame>Time from start of treatment to the first documentation of disease progression or death, whichever occurs first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Duration of Response (DOR) as Assessed by the Investigator</measure>
    <time_frame>Time from first determination of response until first documentation of progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time to Response (TTR) as Assessed by the Investigator</measure>
    <time_frame>Time from start of treatment to first documentation of response</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Overall survival (OS) as Assessed by the Investigator</measure>
    <time_frame>Time from start of treatment to the date of death due to any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Rate of Minimal Residual Disease (MRD) negativity in Blood</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Rate of Minimal Residual Disease (MRD) negativity in Bone Marrow</measure>
    <time_frame>Up to 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum Observed Plasma Concentration (Cmax) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area Under the Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time to Maximum Plasma Concentration (Tmax) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time Taken for Half the Initial Dose Administered To Be Eliminated From The Body (T1/2) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Apparent Clearance (CL/F) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b Apparent volume of distribution (Vz/F) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Steady State Area Under the Concentration-Time Curve of 0- Last Day (AUCLast, ss) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Steady State Maximum Observed Plasma Concentration (Cmax, ss) of BGB-11417</measure>
    <time_frame>Predose up to 112 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Steady State Trough Observed Plasma Concentration (Ctrough, SS) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>: Phase 1b; Steady State Time to Maximum Plasma Concentration (Tmax, ss) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b; Change in AUC of BGB-11417 from Fasted to Fed Condition</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b; Change in Cmax of BGB-11417 from Fasted to Fed Condition</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Mature B-Cell Malignancies</condition>
  <arm_group>
    <arm_group_label>Phase 1a: BGB-11417 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Finding: Cohorts of participants with FL, DLBCL, MZL or transformed NHL, will receive oral BGB-11417 until the maximum tolerated and recommended phase 2 dose can be determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Part A (CLL/SLL Ramp-up) : BGB-11417 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramp-Up Schedule Finding: Participants with CLL/SLL will receive oral BGB-11417 in various ramp-up schedules to determine optimum ramp-up schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Part B (Expansion Cohorts): BGB-11417 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Expansion: Participants with CLL/SLL, FL, DLBCL, MZL or transformed NHL will receive recommended doses of oral BGB-11417 alone as determined from Phase 1a Dose Findings in parallel planned cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-11417</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Phase 1a: BGB-11417 Monotherapy</arm_group_label>
    <arm_group_label>Phase 1b Part A (CLL/SLL Ramp-up) : BGB-11417 Monotherapy</arm_group_label>
    <arm_group_label>Phase 1b Part B (Expansion Cohorts): BGB-11417 Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Part 1 Marginal Zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell
        lymphoma (DLBCL) or transformed B-cell NHL (excluding Richters Transformation) that has
        relapsed or is refractory to at least 1 prior therapy

        Part 2 (CLL/SLL Ramp-up):

        Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that relapsed or been
        refractory to at least 1 prior therapy

        Part 2 (Expansion Cohorts):

        Marginal Zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma
        (DLBCL) or transformed B-cell NHL (excluding Richters Transformation) that has relapsed or
        is refractory to at least 1 prior therapy

        Key Exclusion Criteria:

          1. Prior malignancy within the past 2 years, except for curatively treated basal or
             squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix
             or breast, or localized Gleason score 6 prostate

          2. Known central nervous system (CNS) involvement by lymphoma/leukemia

          3. Known plasma cell neoplasm, prolymphocytic leukemia, history of or currently suspected
             Richter's syndrome

          4. Prior autologous stem cell transplant unless ≥ 3 months after transplant

          5. Prior allogeneic stem cell transplant

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Simpson</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>BCL2 Inhibitor</keyword>
  <keyword>CLL</keyword>
  <keyword>MCL</keyword>
  <keyword>MZL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

